146432-17-9

Basic information

• Product Name: Morpholine, 4-[(2S)-2-hydroxy-1-oxopropyl]-
• CAS NO: 146432-17-9
• Molecular Formula: C7H13NO3
• Molecular Weight: 159.185
• Mol File: 146432-17-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Morpholine, 4-[(2S)-2-hydroxy-1-oxopropyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine, 4-[(2S)-2-hydroxy-1-oxopropyl]-(146432-17-9)
• EPA Substance Registry System: Morpholine, 4-[(2S)-2-hydroxy-1-oxopropyl]-(146432-17-9)

Safety Data

• Hazardous Substances Data: 146432-17-9(Hazardous Substances Data)

Usage

General Description

Morpholine, 4-[(2S)-2-hydroxy-1-oxopropyl]-, also known as morpholinium propionate, is an organic compound with the molecular formula C7H13NO4. It is a derivative of morpholine and is commonly used as a stabilizer in pharmaceutical products, as well as a corrosion inhibitor in the oil and gas industry. This chemical is soluble in water and has a slightly sweet odor. It is classified as a hazardous substance and should be handled and stored with caution due to its potential to cause skin and eye irritation.

Upstream product

• 110-91-8 morpholine 
• 27871-49-4 (S)-Methyl lactate 
• 97-64-3 ethyl 2-hydroxypropionate 
• 687-47-8 (S)-Ethyl lactate 

Downstream Products

• 295788-49-7 N-((2S)-2-p-toluenosulfonyloxypropanoyl)morpholine 
• 295788-52-2 2-((R)-1-morpholinocarbonylethoxy)-4-phthalimidomethylnitrobenzene 
• 295788-54-4 2-((R)-1-morpholinocarbonylethoxy)-4-tert-butoxycarbonylaminomethylnitrobenzene 
• 295788-51-1 2-((R)-1-morpholinocarbonylethoxy)-4-methanesulfonyloxymethylnitrobenzene 
• 295788-53-3 2-((R)-1-morpholinocarbonylethoxy)-4-aminomethylnitrobenzene 
• 295788-50-0 2-((R)-1-morpholinocarbonylethoxy)-4-hydroxymethylnitrobenzene 

Relevant articles and documents

Asymmetric synthesis of naproxen via a pinacol-type reaction

An asymmetric pinacol-type rearrangement was used in the synthesis of (S)-naproxen. The pinacol-type reaction of a sec-tert vicinal diol provided an α-aryl ketone wich was oxidized with sodium hypochlorite in the presence of methanol to the methyl ester of naproxen.

FORUMLATIONS

This invention relates to the use of lactamide compounds of formula (I): CH3CH(OH)C(=O)NR1R2, where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.

STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE

The present invention is related to the stereospecific preparation of 1-[6-(1- ethyl-1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1-yl)-benzyl]- pyrrolidin-2-one, and the intermediates thereof. Another aspect of the invention relates to 1-[6-(1 -ethyl- 1,2-dihydroxy-propyl)-pyridin-3-yl]-3-[2-(4-methyl-piperazin-1- yl)-benzyl]-pyrrolidin-2-one, wherein the carbon atoms having the 1,2-dihydroxy substituents are any of the four diastereomers selected from (R,R), (R,S), (S,R), and (S, S), wherein the carbon three of the pyrrolidin-2-one is (R) or (S), pharmaceutically acceptable salts thereof, solvates thereof, pharmaceutical compositions containing them, and methods using them for in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.